Ambrilia Biopharma Inc. Announces Third Quarter 2006 Results And Provides Update On Lead Development Programs
MONTREAL, QUEBEC--(CCNMatthews - Nov. 14, 2006) - Ambrilia Biopharma Inc. (TSX:AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today its third quarter 2006 results, as well as the conversion of its 4,000,000 Series 1 First Preferred Share and provided an update on its lead development programs.